Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Epilepsy and Driving].
Takagi S, Matsuura M. Takagi S, et al. Brain Nerve. 2017 Oct;69(10):1069-1077. doi: 10.11477/mf.1416200874. Brain Nerve. 2017. PMID: 29042520 Japanese.
Very early-onset of RBD with ADHD: a case report study.
Takagi S, Yamashiro Y, Sugihara G, Takahashi H, Matsuura M. Takagi S, et al. Neurocase. 2020 Feb;26(1):60-63. doi: 10.1080/13554794.2019.1697823. Epub 2019 Nov 28. Neurocase. 2020. PMID: 31777313
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.
Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S, Baba S, Takemoto A, Huang T, Seto Y, Saito M, Funauchi Y, Ae K, Takeuchi K, Fujita N, Katayama R. Takagi S, et al. Oncogene. 2024 Dec 11. doi: 10.1038/s41388-024-03251-6. Online ahead of print. Oncogene. 2024. PMID: 39663392
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
2,106 results